Executive TEAM
Paul Goldenheim, MD Chief Executive Officer & Cofounder
Paul Goldenheim, MD Chief Executive Officer & Cofounder
Paul Goldenheim, MD Chief Executive Officer & Cofounder
Paul Goldenheim, MD brings decades of experience to his role. Dr. Goldenheim is a pulmonary physician and has a long history in pharmaceutical research, development, and management. He has held roles as CSO of Purdue Pharma, President of TransForm Pharmaceuticals (acquired by Johnson & Johnson), Vice-Chairman of Hypnion (acquired by Eli
Paul Goldenheim, MD brings decades of experience to his role. Dr. Goldenheim is a pulmonary physician and has a long history in pharmaceutical research, development, and management. He has held roles as CSO of Purdue Pharma, President of TransForm Pharmaceuticals (acquired by Johnson & Johnson), Vice-Chairman of Hypnion (acquired by Eli Lily), CEO of River Stone Bio, and as a Director of Promedior (acquired by Roche) and Momenta Pharmaceuticals. Dr. Goldenheim received his AB from Harvard College magna cum laude with highest honors in biochemical sciences and his MD from Harvard Medical School.
Diana Meske, PhD Chief Operating Officer & Cofounder
Paul Goldenheim, MD Chief Executive Officer & Cofounder
Paul Goldenheim, MD Chief Executive Officer & Cofounder
Diana Meske, PhD brings over 15 years of pharmaceutical and research experience in multiple facets of leadership and drug development, mainly of analgesics. Dr. Meske's career ad primarily focused on clinical development roles with increasing responsibility, however she has had critical roles in a diversity of functions, including regula
Diana Meske, PhD brings over 15 years of pharmaceutical and research experience in multiple facets of leadership and drug development, mainly of analgesics. Dr. Meske's career ad primarily focused on clinical development roles with increasing responsibility, however she has had critical roles in a diversity of functions, including regulatory, nonclinical, biostatistics, business development, medical affairs, and commercial. She holds a PhD in Medical Pharmacology from the University of Arizona.
Nathaniel Katz, MD, MS Chief Medical Officer & Cofounder
Paul Goldenheim, MD Chief Executive Officer & Cofounder
Nathaniel Katz, MD, MS Chief Medical Officer & Cofounder
Nathaniel Katz, MD, MS brings decades of experience to his role. Dr. Katz considered one of the leading experts on the treatment and clinical study design in pain clinical trials. He is a neurologist and pain management specialist with a distinguished career at Harvard Medical School, Brigham & Women's Hospital, and Dana Farber Cancer I
Nathaniel Katz, MD, MS brings decades of experience to his role. Dr. Katz considered one of the leading experts on the treatment and clinical study design in pain clinical trials. He is a neurologist and pain management specialist with a distinguished career at Harvard Medical School, Brigham & Women's Hospital, and Dana Farber Cancer Institute. He served as Chair of the Advisory Committee, Anesthesia, Critical Care, and Addiction Products Division, United States FDA, during which time he completed a Masters of Science in Biostatistics at Columbia University. Additionally, he is a successful and experienced entrepreneur. In addition to his Masters, Dr. Katz holds an MD from the Medical College of Pennsylvania.
Key advisors
Allan Green, MD, PhD, JD
Allan Green, MD, PhD, JD
Allan Green, MD, PhD, JD
Dr. Green was previously the CEO and cofounder of Osteoanalgesia and Chariton Pharmaceuticals, where SP-101 was initially developed. He brings expertise as a chemist, physician, regulatory attorney, and research scientist with decades of experience in operating management and entrepreneurship.
Lee Simon, MD
Allan Green, MD, PhD, JD
Allan Green, MD, PhD, JD
Dr. Simon was previously a cofounder of Osteoanalgesia and Chariton Pharmaceuticals, where SP-101 was initially developed. He has served as the FDA's Division Director of Analgesics, Anti-inflammatory and Ophthalmologic Drug Products. He brings expertise as a Rheumatologist, research scientist, and regulatory expert.
Stephen DiMagno, PhD
Allan Green, MD, PhD, JD
Stephen DiMagno, PhD
Dr. DiMagno is a key CMC consultant having previously overseen the technical, scientific, and practical aspects of the development of the first commercially scalable manufacturing methods of a HPMA copolymer drug, SP-101, while owned by OsteoAnalgesia.